Anti-hepatitis Agents

Random Miscellaneous Quiz

Can you name the Anti-hepatitis Agents?

Quiz not verified by Sporcle

How to Play
Share
Tweet
Email
Embed
HintAnswer
Use: HBV: Safer for pts w/ decompensated liver dz. For both adults & peds
Group MOA cont. (2) Ribonuclease L (activated by 2'5' oligo A): degrades mRNA.
Telaprevir Class
SE: Nephrotoxicity (at high doses). Potential mitochondrial DNA toxicity
MOA: An adenosine analogue. Structurally similar to adefovir.
P-kinetics:Oral bioavailability not affected by food. Emergence of resistance in long term use.
Telbivudine (Tyzeka) Class
P-kinetics: Synthetic (consensus). SC
P-kinetics: Oral (TID). P450 substrates (potential rx interactions)
P-kinetics: Clinical resistance is rare. Oral bioavailability decreased by food (taken w/ empty stomach). Renal elimination (serum concentration increased w/ altered kidney activit
MOA: A guanisine analog. Inhibits all 3 functions of HBV RNA-dependent DNA polymerase (base priming, reverse transcription of the -strand, synthesis of the + strand of HBV DNA.
Group MOA cont: Associated with mitochondrial DNA toxicity (by inhibiting DNA polymerase gamma)
MOA: A cytosine analogue
P-kinetics: Prolonged intracellular half-life in HBV (than in HIV). Rapid oral absorption; eliminated unchanged. Used at lower doses for hepatitis than for AIDS.
Use: The most potent anti-HBV agent. Adults only
Lamivudine (3TC, Heptovir) Class
Use: Effective suppression of HBV DNA, normalization of ALT & reducing HBeAg. Adults only
P-kinetics: Slower clearance (less frequent dosing). Dosage adjustment is needed in renal dysfunction
SE: Flu-like symptoms (fever, chills, myalgias, malaise). Neurotoxicity, myelosuppression, fatigue (chronic use). Transient hepatic enzyme elevation.
SE: HA, fatigue, nausea. Potential mitochondrial toxicity (lactic acidosis & hepatic steatosis)
Group MOA cont. (3) Protein kinase (activated by dsRNA): phosphorylates/inhibits eIF-2, therefore blocking PRO synthesis
PEG-IFN α-2a/2b class
SE: Increased pancreatitis in HIV/HBV pts. Emergence of resistance (mutations of DNA polymerase)
IFN alfacon-1 class
Contraindications: Pts w/ uncorrected anemia, ESRD, preggo. Teratogenic: avoid pregnancy for > 6 mos thereafter
HintAnswer
P-kinetics: Higher rate of complete response & less resistance vs. adefovir
PEG-IFN α-2a Class
Group MOA: 3 major enzymes are activated by IFN-JNK/STAT signaling pathway: (1) 2',5' oligo A synthase: produces 2'5' oligo A.
MOA: Serine protease inhibitors. Bind to inhibit HCV non-structural protein NS3
Adefovir dipivoxil (Hepsera) Class
Group MOA: Competively inhibit HBV DNA polymerase +/- incorporate into viral DNA causing chain termination. Phosphorylated to active forms intracellularly by cellular kinases.
Group P-kinetics: Pills once a day for a year or longer
MOA: A prodrug (a guanosine nucleoside analogue). Phosphorylated by host cell enzymes; inhibits viral RNA-dependent polymerases.
P-kinetics: Natural. SC or IM
Use: Lamivudine-resistant HBV. Adults only
Drug MOA: PEG = polyethylene glycol
Use: HBV treatment adults only
Boceprevir Class
P-kinetics: Lipophilic (pivoxil) moiety enhances oral bioavailability.
Contraindications: Hepatic decompensation, autoimmune dz, cardiac arrhythmia, pregnancy
Tenofovir Class
IFN α-2a/2b class
MOA: A prodrug of adefovir (adenosine analogue). Slows suppression of HBV DNA; least seroconversion
Entecavir (Baraclude) Class
Use: Improve therapeutic response in pts (>18 yo) w/ HCV genotype 1 when combined w/ IFN/ribavirin
SE: Anemia, neutropenia, dysgeusia, skin rash (esp. telaprevir), increased QT intervals (telaprevir)
IFN α-2b Class
MOA: A thymidine analog
P-kinetics: Oral bioavailability increased with high-fat meal, decreased with antacid.
SE: Dose-dependent hemolytic anemia. Depression, fatigue, irritability, nausea, insomnia.

You're not logged in!

Compare scores with friends on all Sporcle quizzes.
Sign Up with Email
OR
Log In

You Might Also Like...

Show Comments

Extras